Drug intelligence / Profile preview

autologous Epstein-Barr virus-specific cytotoxic T lymphocytes

Development stage: Phase 2
Lead developer: Atara Biotherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) represent an adoptive cell therapy where a patient's own T cells are expanded and directed to specifically target and eliminate cells infected with the Epstein-Barr virus (EBV). This therapeutic approach has demonstrated safety and efficacy in the treatment of EBV-associated posttransplantation lymphoproliferative disorders (PTLDs) in solid organ transplant recipients. Research is ongoing to enhance the therapy, including modifications to make these cells resistant to immunosuppressive drugs such as tacrolimus (FK506) by knocking down the expression of FKBP12. This modification aims to improve the long-term persistence of transferred EBV-CTLs and enhance EBV-specific immune surveillance in patients at high risk of PTLD after transplantation.

Other names: autologous EBV-specific CTLautologous EBV-CTLautologous Epstein-Barr virus (EBV)-specific cytotoxic T cells

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on autologous Epstein-Barr virus-specific cytotoxic T lymphocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous Epstein-Barr virus-specific cytotoxic T lymphocytes.

Explore the full profile